MindHYVE.ai™ and Islamabad Diagnostic Centre Forge Strategic Alliance to Launch AGI-Powered Diagnostic Intelligence Across Pakistan
ISLAMABAD, May 22, 2025 /CNW/ -- In a groundbreaking move to elevate clinical diagnostics nationwide, MindHYVE.ai™, a U.S.-based pioneer in orchestrated agentic AI and swarm-intelligent systems, has signed a formal Memorandum of Understanding (MoU) with Islamabad Diagnostic Centre (IDC). The collaboration will see the deployment of Chiron and Ava-AutoNarrator™—two proprietary, AGI-powered agents—across IDC's core diagnostic workflows.
Initially launching at flagship centers in Islamabad (F-8 Markaz) and Lahore (DHA Phase 4), the pilot will introduce a multi-agent diagnostic intelligence layer, enhancing decision precision, speed, and reproducibility in radiology and laboratory services.
"This isn't just AI—it's agentic intelligence in action," said Belal Faruki, Founder & CEO of MindHYVE.ai™. "By fusing swarm intelligence with domain-specific reasoning models, we're equipping clinicians with AI collaborators that learn, adapt, and elevate patient outcomes—ethically and transparently."
Key Innovations:
Chiron – A medical diagnostic reasoner, part of MindHYVE.ai™'s Ava-Agent architecture, performs pre-diagnostic inference and real-time anomaly detection across radiological and laboratory datasets.
Ava-AutoNarrator™ – A semi-autonomous narrative generation agent, trained on clinical ontologies, that synthesizes structured reports aligned with ICD and HL7 standards.
Agentic Coordination Layer – MindHYVE.ai™'s Swarm AI Framework orchestrates agents in real-time—enabling self-organization, priority optimization, and contextual reasoning across patient records.
Secure PACS/LIS Integration – Seamless, encrypted integration with IDC's Picture Archiving and Communication Systems (PACS) and Laboratory Information Systems (LIS).
Three-Phase Rollout Strategy:
Phase 1 – Ground Launch: Initial deployment, radiologist/lab team onboarding, and system calibration.
Phase 2 – Reasoner Tuning: AGI model refinement, cross-clinic feedback loops, and clinical data harmonization across 5–7 IDC locations.
Phase 3 – Nationwide Readiness: DRAP-compliant licensing, agent swarm scaling, and full-stack intelligence across IDC's 130+ branches.
Ethical Intelligence Commitment
All systems will be governed under MindHYVE.ai™'s Ethical AGI Protocol, including:
Human-in-the-loop validation
Encrypted patient data pathways
Collaborative oversight with DRAP and PNAC
Explainable diagnostic decisions using Ava-Fusion™ reasoning models
"MindHYVE.ai™'s orchestrated AGI reflects our vision of scalable, accessible diagnostics," said Dr. Rizwan Uppal, Founder & CEO of IDC. "This alliance ushers in a new era of intelligent healthcare, anchored in ethics and excellence."
About MindHYVE.ai™
Headquartered in Newport Beach, California, MindHYVE.ai™ builds domain-specific AGI agents, multi-agent orchestration systems, and the Ava-Fusion™ family of reasoning models—driving intelligent transformation in diagnostics, infrastructure, and national systems.
Media Contact
Marc Ortiz
Email: [email protected]
SOURCE MindHYVE.ai, Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
an hour ago
- Cision Canada
Bybit donates over $300,000 to support earthquake relief in Myanmar and Thailand
DUBAI, UAE, June 5, 2025 /CNW/ -- Bybit, the world's second-largest cryptocurrency exchange by trading volume, has pledged over $300,000 to support earthquake relief efforts and improve access to clean water and medical aid in Myanmar and Thailand, following the devastating 7.7-magnitude earthquake that struck near Mandalay, Myanmar, on March 28. The earthquake caused widespread destruction in central Myanmar and was strongly felt across the region, including in parts of Thailand. Communities in both countries have been affected, with many left without access to basic necessities. Bybit's contribution has supported trusted local partners delivering critical aid on the ground, including emergency supplies, food, clean drinking water, and medical care. In Myanmar, support will be directed to Spring Development Bank, Myan Crypto, ANTS, and Bybit Myanmar, in collaboration with Sagaing Region Urgent Earthquake Relief Committee. These partners are providing urgent relief through water access, food distribution, community outreach, and blockchain-based financial assistance. In Thailand, Bybit has been working with the Thai Red Cross Society, Poh Teck Tung Foundation, and Siriraj Foundation. The funding will help deliver emergency shelter, healthcare, rescue operations, and long-term recovery support for communities affected by the earthquake and its aftermath. "Our hearts go out to everyone affected by this tragic disaster," said Helen Liu, Chief Operating Officer at Bybit. "At Bybit, we believe in the power of community and the urgency of standing together during moments of crisis. We are honored to support the people of Myanmar and Thailand through partners who are working tirelessly to deliver life-saving aid." #Bybit / #TheCryptoArk About Bybit Bybit is the world's second-largest cryptocurrency exchange by trading volume, serving a global community of over 70 million users. Founded in 2018, Bybit is redefining openness in the decentralized world by creating a simpler, open and equal ecosystem for everyone. With a strong focus on Web3, Bybit partners strategically with leading blockchain protocols to provide robust infrastructure and drive on-chain innovation. Renowned for its secure custody, diverse marketplaces, intuitive user experience, and advanced blockchain tools, Bybit bridges the gap between TradFi and DeFi, empowering builders, creators, and enthusiasts to unlock the full potential of Web3. Discover the future of decentralized finance at
Cision Canada
7 hours ago
- Cision Canada
ERA Congress: Long-term data show sustained efficacy and safety of zigakibart in patients with IgA nephropathy
VIENNA, June 4, 2025 /CNW/ -- New 100-week data from the ongoing Phase 1/2 study of zigakibart, an investigational anti-APRIL monoclonal antibody, reinforce its potential as a disease-modifying treatment for IgA nephropathy (IgAN). Findings presented today at the 62 nd ERA Congress demonstrate sustained proteinuria remission, stable kidney function, and a reassuring safety profile. IgAN is the most common form of glomerular disease worldwide and a frequent cause of chronic kidney disease. Its pathogenesis is marked by inflammation and progressive kidney damage, which can lead to kidney failure. Many patients are unaware they have the condition until significant kidney damage has occurred, and 50% of IgAN patients will ultimately develop kidney failure. By targeting the APRIL pathway and reducing production of pathogenic galactose-debecause ofgA1), zigakibart addresses a key driver of disease progression. "Zigakibart is designed to intercept the initiating factor in IgAN pathogenesis, offering a new approach that may halt or significantly delay progression", explained lead investigator Professor Jonathan Barratt. The ADU-CL-19 trial included 40 adults with biopsy-confirmed IgAN and persistent proteinuria despite stable supportive therapy. Patients received zigakibart every two weeks via intravenous infusion or subcutaneous injection, in addition to maximally tolerated renin–angiotensin system inhibitors (RASi) unless RASi-intolerant – demonstrating efficacy beyond standard care. At Week 100, proteinuria was reduced by 60% from baseline. Over half of patients (55%) reached <500 mg/24 h, and 31% achieved <300 mg/24 h, indicating deeper remission. Estimated glomerular filtration rate (eGFR) remained stable across subgroups. "The consistency of eGFR stabilisation over 100 weeks, even across proteinuria response groups, is particularly encouraging," said Prof. Barratt. Treatment also led to sustained reductions in serum immunoglobulins, including a 74% drop in IgA and pathogenic Gd-IgA1, consistent with APRIL pathway inhibition. Zigakibart was well tolerated throughout. Most adverse events were mild or moderate, with no treatment-related serious infections or discontinuations. Infections were the most common AEs; the study coincided with a high prevalence of COVID-19. This is the longest duration of eGFR stabilisation reported for an anti-APRIL agent in IgAN. "These long-term results build confidence in zigakibart as a potential cornerstone therapy for IgAN," said Prof. Barratt. "We're excited to see how the upcoming Phase 3 trials will further define its role." The global Phase 3 BEYOND study is now evaluating zigakibart in a broader population, with primary proteinuria endpoints at 40 weeks and long-term kidney function through 104 weeks.
Cision Canada
7 hours ago
- Cision Canada
OceanaGold Reports Voting Results from its 2025 Annual General and Special Meeting
VANCOUVER, BC, June 4, 2025 /CNW/ - OceanaGold Corporation (TSX: OGC), (TSX: OTCQX) (TSX: OCANF) ("OceanaGold" or the "Company") is pleased to report the voting results from the Company's 2025 Annual General and Special Meeting of Shareholders (the "Annual Meeting") held today. A total of 538,458,035 common shares were voted at the meeting, representing 77.12% of the votes attached to all outstanding common shares. Shareholders voted in favour of each of the items of business at the Annual Meeting as follows: Election of Directors Resolutions electing each of the director nominees listed in OceanaGold's Management Information Circular dated April 23, 2025 as directors of the Company were passed by ordinary resolution. Detailed results of the vote for each director are set out in the table below: Share Consolidation A special resolution approving the consolidation of all issued and outstanding common shares of the Company on a consolidation ratio of up to three (3) pre-consolidation common shares for one (1) post-consolidation common share (the "Consolidation") was passed. The Company is exploring the benefits of a dual listing of its common shares on a major U.S. exchange, including the New York Stock Exchange, for a potential listing in the first half of 2026. The Company believes a U.S. listing could lead to increased interest by a wider audience of potential investors and result in increased marketability and trading liquidity. The principal reason for the Consolidation is to raise the per share trading price of the common shares in order to better comply with minimum trading price requirements of such exchanges. Subject to approval by the Toronto Stock Exchange, OceanaGold expects the Consolidation to be effective on or around June 23, 2025, and intends to issue a detailed press release to provide a further update and final details on the Consolidation. Appointment of Auditor A resolution appointing PricewaterhouseCoopers LLP (PWC Canada) as the auditor of the Company for the ensuing year and authorizing the board of the Company to fix their remuneration was passed. Advisory Vote on Executive Compensation A non-binding resolution on the Company's approach to executive compensation was passed. Virtual-Only Meetings A resolution approving the Company to hold the 2026 Annual General Meeting of Shareholders exclusively in a virtual-only format was passed. Amendments to the Company's Articles A special resolution approving amendments to the Company's articles was passed. About OceanaGold OceanaGold is a growing intermediate gold and copper producer committed to safely and responsibly maximizing the generation of Free Cash Flow from our operations and delivering strong returns for our shareholders. We have a portfolio of four operating mines: the Haile Gold Mine in the United States of America; Didipio Mine in the Philippines; and the Macraes and Waihi operations in New Zealand. Cautionary Statement for Public Release This press release contains certain "forward-looking statements" and "forward-looking information" (collectively, "forward-looking statements") within the meaning of applicable Canadian securities laws which may include, but is not limited to, statements with respect to the Company being listed on a major U.S. exchange, including such dual listing leading to increased interest by a wider audience of potential investors, increased marketability and trading liquidity and the expected timing for such listing, and the anticipated timing and effects of the completion of the Consolidation. Forward-looking statements and information relate to future performance and reflect the Company's expectations regarding the generation of Free Cash Flow, execution of business strategy, future growth, future production, estimated costs, results of operations, business prospects and opportunities of OceanaGold and its related subsidiaries. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always, using words or phrases such as "expects" or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "estimates" or "intends", or stating that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved) are not statements of historical fact and may be forward-looking statements. Forward-looking statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those expressed in the forward-looking statements. They include, among others, those risk factors identified in the Company's most recent Annual Information Form prepared and filed with securities regulators which is available on SEDAR+ at under the Company's name and on the Company's website. There are no assurances the Company can fulfil forward-looking statements. Such forward-looking statements are only predictions based on current information available to management as of the date that such predictions are made; actual events or results may differ materially as a result of risks facing the Company, some of which are beyond the Company's control. Although the Company believes that any forward-looking statements contained in this press release is based on reasonable assumptions, readers cannot be assured that actual outcomes or results will be consistent with such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements and information, whether as a result of new information, events or otherwise, except as required by applicable securities laws.
